Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Users Online: 6013 | Home Print this page Email this page Small font size Default font size Increase font size
Year : 2012  |  Volume : 32  |  Issue : 5  |  Page : 92

PA01.42. New alternative therapies in mild cognitive impairment

1 "Vasile Goldis" Western University of Arad, Romania
2 Psychiatric Hospital of Mocrea, Romania

Correspondence Address:
Delia Marina Podea
"Vasile Goldis" Western University of Arad
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Purpose: Mild cognitive impairment (MCI) is a frequent clinical entity, considered today to be a prodromal stage of Alzheimer's dementia, but not having until now a standardized pharmacological treatment. The aim of this study is to follow the outcome of the patients diagnosed with MCI non treated and treated with nootropics, alternative herbal agents, and cholinesterase inhibitors. Method: The study comprises a number of 200 patients (over 60 years) diagnosed with MCI. The patients were evaluated using MMSE (Mini Mental State Evaluation) at the inclusion into the study and after 1 year of treatment. The patients were divided in four different groups: Group A - 50 patients diagnosed with MCI treated with Piracetamum 1600mg/day, Group B - 50 patients diagnosed with MCI treated with Rhodiola rosea, 2 capsules/day, Group C - 50 patients diagnosed with MCI treated with Galantamine (16mg/day), Group D - 50 patients diagnosed with MCI non treated Result: The average of MMSE scores at screening was 23.96 points for group A, 24.16 points for group B, 23.96 for group C and 24.5 points for group D. After 1 year of treatment, cognitive performance improves with 2.12 points for Group A, 1.97 points for Group B, 2.04 points for Group C and without any improvement for Group D. Conclusion: Comparing the outcome of treated and non-treated groups, we observed that the early treatment of mild cognitive impairment delay the transition to dementia. The outcome of the treated groups after 1 year of pharmacological treatment was approximately the same. This study proves the necessity of early treatment and of the enlargement of therapies in mild cognitive impairment. The acceptance of nonconventional therapies can change the relationships between physicians and well educated patients who more frequently advocate for a broad range of treatment choices.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded31    
    Comments [Add]    

Recommend this journal